A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes
Latest Information Update: 05 Dec 2014
At a glance
- Drugs Pyridoxamine (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioStratum
Most Recent Events
- 05 Nov 2010 New trial record.